Recipharm has unveiled plans to invest €40 million over the next three years to help pharmaceutical companies prepare for the implementation of new serialization regulations. The move by the company comes as the announcement of the EU Falsified Medicines Directive (EUFMD) Safety Features Delegated Regulation is released. This means that the serialization of licensed drug products will be a legal requirement for companies in the EU from early 2019. Recipharm already provides serialized prod...